Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ARS Pharmaceuticals Inc shares valued at $190,050 were sold by Dorsey Brian on Nov 13 ’25. At $8.71 per share, Dorsey Brian sold 21,828 shares. The insider’s holdings dropped to 10,789 shares worth approximately $0.12 million following the completion of this transaction.
Also, Chakma Justin sold 166,380 shares, netting a total of over 1,476,147 in proceeds. Following the sale of shares at $8.87 each, the insider now holds 0 shares.
Before that, BRIAN T DORSEY had added 21,828 shares to its account. In a trade valued at $190,050, the Officer bought ARS Pharmaceuticals Inc shares for $8.71 each.
Analysts at Roth Capital started covering the stock with ‘”a Buy”‘ outlook in a report released in early September. As of March 07, 2025, Scotiabank has initiated its “Sector outperform” rating for SPRY. Earlier on February 10, 2025, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for SPRY stock.
Analyzing SPRY Stock Performance
On last trading session, ARS Pharmaceuticals Inc [NASDAQ: SPRY] plunged -5.94% to $11.09. The stock’s lowest price that day was $11.07, but it reached a high of $11.7405 in the same session. During the last five days, there has been a surge of approximately 1.28%. Over the course of the year, ARS Pharmaceuticals Inc shares have dropped approximately -2.38%.
Support And Resistance Levels for ARS Pharmaceuticals Inc (SPRY)
RSI (Relative Strength Index) is 50.95 on the 14-day chart, showing neutral technical sentiment.
Is ARS Pharmaceuticals Inc subject to short interest?
Stocks of ARS Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.16 million shares to 20.51 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 20.66 million shares. A decline of -0.76% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.95 of the overall float, the days-to-cover ratio (short ratio) decline to 12.95.
Which companies own the most shares of ARS Pharmaceuticals Inc (SPRY)?
In terms of ARS Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 31 in the next 12 months, up nearly 162.93% from the previous closing price of $11.79. Analysts anticipate ARS Pharmaceuticals Inc stock to reach 32 by 2026, with the lowest price target being 30. In spite of this, 4 analysts ranked ARS Pharmaceuticals Inc stock as Buy at the end of 2026.
